Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2018 Jul 3;17(9):1893–1901. doi: 10.1158/1535-7163.MCT-17-0600

Fig. 4.

Fig. 4

Improved pharmacodynamic response and orthotopic survival in GBM108-VEGFA

A) p21 expression in GBM108-Vector and GBM108-VEGFA after SAR405838 treatment in orthotopic tumors (scale bar = 200 um). B) Quantitation of SAR405838 effect on p53 signaling. Mice with established orthotopic tumors were treated with SAR405838 or placebo and then processed for p21 IHC. The percentage of p21-positive nuclei per high powered field in GBM108-Vector versus GBM108-VEGFA after placebo or SAR405838 (5 mice per group) are presented as mean ± standard deviation. C, D) Orthotopic survival, GBM108-Vector (n=10 per group) vs GBM108-VEGFA (n=9 for placebo and n=10 for the treatment group). SAR405838 was dosed at 50 mg/kg p.o. qd until moribund. * P<0.05, ** P<0.01, *** P<0.001.